The deubiquitinating enzyme USP17 is associated with non-small cell lung cancer (NSCLC) recurrence and metastasis
Metrics: PDF 2073 views | HTML 2082 views | ?
Cheryl McFarlane1, Suzanne McFarlane2, Ian Paul2, Kenneth Arthur2, Michael Scheaff3, Keith Kerr4, Michael Stevenson5, Dean A. Fennell2,6 and James A. Johnston1,7
1 Centre for Infection and Immunity, Queen’s University Belfast, Belfast, Northern Ireland, UK
2 Centre of Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Sciences, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, Northern Ireland, UK.,
3 Department of Pathology, Barts & London NHS Trust, London, UK
4 Department of Pathology, University of Aberdeen, Scotland, UK.
5 Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, Northern Ireland, UK
6 Current address: University of Leicester & Leicester University Hospitals, MRC Toxicology Unit, Hodgkin Building, Leicester
7 Current address: Amgen, One Amgen Center Dr., Thousand Oaks, CA
Cheryl McFarlane, email:
Keywords: ubiquitination, deubiquitination, USP17, NSCLC, metastasis
Received: August 12, 2013 Accepted: September 30, 2013 Published: October 3, 2013
USP17 is a cell cycle regulated deubiquitinating enzyme that is highly expressed in tumor-derived cell lines and has an established role in cell proliferation and chemotaxis. This is the first study to examine the clinical significance of USP17 expression in non-small cell lung cancer (NSCLC). USP17 was overexpressed in both squamous and adenocarcinoma NSCLC tissue. Patients with USP17 positive tumors had significantly reduced recurrence-free survival than patients with USP17 negative tumors. Moreover, USP17 was more highly expressed in patients with recurrence of disease at distant sites, suggesting that USP17 levels may correlate with NSCLC distant metastases. Overall, these findings establish USP17 as a potentially valuable novel biomarker for metastatic lung cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.